The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE
OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
10X Genomics Inc. COM 88025U109 22,875 300,000 SH   SOLE   300,000 0 0
89Bio Inc COM 282559103 25,206 958,765 SH   SOLE   958,765 0 0
Adverum Biotechnologies Inc COM 00773U108 10,901 946,234 SH   SOLE   946,234 0 0
Axsome Therapeutics Inc COM 05464T104 160,001 1,547,994 SH   SOLE   1,547,994 0 0
Bellerophon Therapeutics COM 078771102 134 383,955 SH   SOLE   383,955 0 0
Constellation Pharmaceuticals COM 210373106 118,540 2,516,242 SH   SOLE   2,516,242 0 0
Forty Seven Inc COM 34983P104 20,330 516,381 SH   SOLE   516,381 0 0
Intra-Cellular Therapies Inc COM 46116X101 19,728 575,000 SH   SOLE   575,000 0 0
Iveric Bio Inc COM 46583P102 14,584 1,699,797 SH   SOLE   1,699,797 0 0
Kalvista Pharmaceuticals COM 483497103 11,041 619,905 SH   SOLE   619,905 0 0
Marinus Pharmaceuticals Inc COM 56854Q101 10,835 5,016,164 SH   SOLE   5,016,164 0 0
Mersana Therapeutics Inc COM 59045L106 8,947 1,561,389 SH   SOLE   1,561,389 0 0
Milestone Pharmaceuticals Inc COM 59935V107 33,085 2,066,529 SH   SOLE   2,066,529 0 0
Myovant Sciences Ltd COM G637AM102 7,066 455,255 SH   SOLE   455,255 0 0
Nextcure Inc COM 65343E108 6,742 119,693 SH   SOLE   119,693 0 0
Obseva SA COM H5861P103 3,095 810,264 SH   SOLE   810,264 0 0
Protagonist Therapeutics Inc COM 74366E102 571 80,929 SH   SOLE   80,929 0 0
Relmada Therapeutics Inc COM 75955J402 29,950 767,938 SH   SOLE   767,938 0 0